How to Help Your Patients Find Nemluvio in Stock: A Provider's Guide

Prescribing Nemluvio (nemolizumab-ilto) is only the first step. Actually getting it into your patient's hands requires navigating a specialty pharmacy enrollment process, insurance prior authorization, and multiple patient support programs — all while your patient may be dealing with severe itching, sleeplessness, and significant distress. This guide gives you a step-by-step framework to streamline Nemluvio access for your patients in 2026.

Step 1: Confirm Eligibility and Document Your Clinical Rationale

Before initiating the enrollment process, ensure your documentation is PA-ready. Insurance reviewers will scrutinize clinical notes, so proactively document:

Confirmed diagnosis (PN per L28.1 or AD per L20.0-L20.9) with documentation of moderate-to-severe disease

Disease severity measures: IGA score, peak pruritus NRS score, EASI (for AD), BSA affected, and impact on quality of life and sleep

Prior treatment history: topical corticosteroids (strength, duration, outcome), topical calcineurin inhibitors, phototherapy, and systemic therapies tried

For AD payers requiring biologic step therapy: documentation of prior dupilumab trial and outcome (inadequate response, intolerance, or contraindication)

Step 2: Pre-Screen Vaccination Status

Before initiating Nemluvio, the prescribing information recommends completing all age-appropriate vaccinations. Live vaccines should not be given during Nemluvio treatment because nemolizumab may reduce vaccine efficacy. Review your patient's vaccination history at the prescribing visit and update as needed before starting therapy.

Step 3: Complete the GPS for Nemluvio Enrollment Form

The GPS Enrollment Form (available at nemluviohcp.com or by calling 1-855-636-5884) is the gateway to all Galderma patient support programs and specialty pharmacy dispensing. Key sections to complete:

Prescriber section: Full prescriber name, NPI, DEA number, practice address, fax, and signature

Patient section: Name, DOB, address, phone, insurance ID, and patient authorization signature

Program elections: Check the Quick Start box for treatment-naïve commercially insured patients; elect copay assistance; indicate if PAP is needed for uninsured patients

Free Goods prescription: For Quick Start, include a separate Free Goods prescription signed by the prescriber — this is a common omission that delays Quick Start delivery

Step 4: Managing the Prior Authorization Process

The specialty pharmacy's benefit investigation team will initiate the PA process, but your office plays a critical role. When the pharmacy or insurer contacts you:

Respond promptly to requests for additional clinical documentation — delays on your end extend the patient's wait

Be prepared for peer-to-peer calls with the insurer's medical director — schedule promptly when requested

If denied, immediately initiate an appeal — submit a letter of medical necessity emphasizing the patient's disease burden, prior treatment failures, and clinical urgency

Step 5: Counseling Your Patient on What to Expect

Set clear expectations to prevent frustration and improve adherence:

Nemluvio is given by subcutaneous injection every 4 weeks (monthly); loading dose is 60 mg (two pens), then 30 mg monthly for most patients

Itch relief can begin as early as 48 hours for some patients with PN; full clinical response for skin lesions may take weeks to months

For AD, continue topical corticosteroids or calcineurin inhibitors as directed alongside Nemluvio — it is approved for use in combination

Drug is delivered to the home — patient should store in refrigerator and allow to reach room temperature 30-45 minutes before injection; do not microwave or apply heat

How medfinder Complements Your Practice

When patients encounter barriers finding Nemluvio — whether due to incomplete enrollment, PA delays, or insurance transitions — medfinder calls pharmacies near them to identify which ones can fill the prescription. Directing patients to medfinder.com/providers gives them a hands-on tool to resolve access issues. For a full clinical overview of Nemluvio access challenges, see our provider shortage briefing.